ASH 2022 | Evaluating dexamethasone-sparing regimens in frail patients with newly diagnosed myeloma
Meral Beksac, MD, Ankara University, Ankara, Turkey, shares some insights into the IFM2017-03 trial (NCT03993912), which is comparing daratumumab and lenalidomide (DR) without long-term dexamethasone to lenalidomide-dexamethasone (Rd) in frail patients with newly diagnosed multiple myeloma (NDMM). This dexamethasone-sparing regimen demonstrated promising responses and an encouraging safety profile. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
One of the important abstracts presented during this ASH meeting is by Salomon Manier at the IFM Group. They have focused on patients who are frail, about the age of 60, and who are not eligible for transplant. And they have randomized one to two patients to Dara-Rd versus Rd, the standard regimen. And what they did was they reduced steroids in the Dara arm after two cycles...
One of the important abstracts presented during this ASH meeting is by Salomon Manier at the IFM Group. They have focused on patients who are frail, about the age of 60, and who are not eligible for transplant. And they have randomized one to two patients to Dara-Rd versus Rd, the standard regimen. And what they did was they reduced steroids in the Dara arm after two cycles. And this is very important among frail, elderly patients since steroids are really very toxic, and especially for the elderly, and moreover for the frail patients. So, thus, based on their data, which shows that the responses are improved by adding Dara, and by sacrificing from steroids, you don’t lose that response effect, and PFS is not impaired either. And discontinuation so far in both arms seem to be equivalent. So, for future, this can be an option. I think we need longer follow-up for sure, but getting rid of steroids for the elderly, after the Italians now, is now a popular approach by the French myeloma experts. So, it’s going to be a valid option for the near future.
Read more...
Disclosures
Sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Oncopeptides: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
